Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesGastroenterologyAlaska Medicaid DAA Coverage Prior Auth | OpenPaye…
    Ask Trek AI about this page
    CurrentAlaska MedicaidPolicy N/A

    Direct Acting Antivirals for Hepatitis C (HCV) — Coverage Criteria

    Customize your policy alerts

    Sign up for all Alaska Medicaid policy alerts

    Know when Alaska Medicaid releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Prior authorization and quantity limit policy for FDA‑approved direct acting antiviral (DAA) medications for treatment of chronic hepatitis C virus (HCV) infection for Alaska Medicaid members, including approval criteria, authorized regimens, and renewal requirements.

    Policy Summary
    PayerAlaska Medicaid
    PolicyDirect Acting Antivirals for Hepatitis C (HCV) — Coverage Criteria
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateN/A
    Last ReviewSep 22, 2017
    Next Review DateN/A
    Key ActionSubmit prior authorization with documentation of chronic HCV diagnosis, genotype, hepatic status (Child‑Pugh), prior therapy history, patient readiness attestation, and plan for SVR12 monitoring.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    All genotypesHCV genotypes covered
    ≥18 (12–18 w/ specialist)Age eligibility

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    MavyretPreferred agent
    SVR12 requiredPost-therapy follow-up
    Child-Pugh B/CSpecialist requirement

    Coverage and Medical Necessity Criteria

    Initial Authorization Criteria

    Covered when ALL of the following are met for initial authorization:

    Initial Authorization: 1. Diagnosis of chronic Hepatitis C infection; AND 2. Documentation of chronic hepatitis C infection status, HCV genotype, viral resistance-status (when applicable), hepatic status including Child-Pugh score, and HCV viral load is included in the authorization request; AND 3. Adult patient age ≥ 18 years (OR youth aged 12–18 when managed directly or in consultation by a specialist); AND 4. Documentation of prior HCV therapies, including dates, whether therapy was completed or discontinued, and if discontinued the reason, and any viral resistance-status; AND 5. Patient readiness assessment completed and patient attestation of compliance submitted and on file in the medical record; AND 6. Patient agrees to complete the regimen and has signed attestation acknowledging regimen completion, reinfection risk, and liver‑damage contributors; AND 7. Prescriber agrees to maintain HCV RNA levels obtained at 12 weeks post‑therapy to demonstrate Sustained Virologic Response (SVR) and retain records available upon request.none

    All items must be documented in the PA request or medical record

    Renewal and Extended Duration Criteria

    Renewal/extended duration covered when ALL of the following are met:

    Renewal Authorization: 1. For regimens with durations longer than 16 weeks, HCV RNA may be required to be submitted for treatment week 4 in sufficient time for renewal review; AND 2. HCV RNA must be < 25 IU/mL at treatment week 4; AND 3. Prescriber must maintain documentation of HCV RNA levels at treatment weeks 4 and 8 and at 12 weeks post‑therapy (SVR12), available upon request; AND 4. Extended durations will not be approved if there is no clinical evidence of benefit or if the need for extension was precipitated by patient non‑compliance; AND 5. Extended authorization or re‑authorization will not be granted for treatment failure resulting from a pharmacy dispensing error (pharmacy responsible); AND 6. Lost or stolen medication replacement requests will not be authorized.HCV RNA <25 IU/mL at week 4

    Applies to renewal/extension requests

    Resistance testing requirement: If the selected regimen or FDA labeling requires resistance‑associated polymorphism testing, the required testing must be completed and results submitted with the request; testing may also be required if deemed medically necessary by the clinical reviewer prior to approval.as specified by regimen/FDA

    Testing required for certain regimens

    Regimen Authorization and Specialist Restriction

    Regimen selection rules and specialist restrictions:

    Preferred regimens: Mavyret is the preferred agent for many genotypes and treatment‑experience scenarios (e.g., treatment‑naïve without cirrhosis: 8 weeks; compensated cirrhosis Child‑Pugh A: 12 weeks for many genotypes; selected genotype 3 scenarios: 16 weeks as noted in the regimen table).durations per policy table

    Refer to the policy table for exact genotype and treatment‑experience mappings

    When preferred agent cannot be used: If the preferred agent cannot be used due to a documented clinical contraindication, alternative agents (for example, Zepatier for certain GT1/4 indications or Epclusa for certain GT2/3 indications) are allowed but are restricted to specialist prescribing or require consultation with a specialist; documentation of the specific clinical contraindication must be submitted with the authorization request.documented clinical contraindication

    Specialist restriction and FDA‑approved indication required

    Requests for treatment of acute hepatitis C infection are excluded from coverage and will be denied. The policy’s denial criteria explicitly list a request for diagnosis of acute hepatitis C infection as a basis for denial.

    Combination therapy including ribavirin is contraindicated in patients who are pregnant and in men whose partners are pregnant because of the risk of birth defects and fetal death. Documentation of pregnancy risk and appropriate counseling must be considered and provided when ribavirin exposure is possible; absence of such consideration is a trigger for denial.

    Agents that are FDA-approved but for which clinical benefit has not been established will not be approved under this policy. In addition, use of a non-preferred agent without a documented clinical contraindication to preferred agents or without trial of an appropriate preferred option is not supported and may be denied.

    What Providers Must Do / Authorization Requirements

    Prior Authorization

    Prior Authorization Required

    Prior authorization is required for Direct Acting Antivirals (DAAs) for chronic hepatitis C. Approval requires meeting the policy clinical criteria and submission of required documentation. Prescribers must perform a patient readiness assessment and submit a signed patient attestation of treatment compliance.

    • Prior authorization required for all DAA requests
    • Prescriber must perform patient readiness assessment and submit signed attestation
    • Approval contingent on meeting documented clinical criteria
    Step Therapy

    Preferred Agent Requirement / Step Therapy

    Alaska Medicaid requires use of preferred HCV agents (for example, Mavyret) when a medically appropriate preferred agent is available. A non-preferred agent will only be approved if there is a documented clinical reason (e.g., intolerance, contraindication, or prior treatment failure) supporting medical necessity for the non-preferred product.

    Definitions and Key Terms

    SVR12 — Sustained virologic response at 12 weeks post‑therapy
    DefinitionSustained virologic response measured 12 weeks after completion of therapy (SVR12).
    Prescriber responsibilityPrescriber must maintain documentation of HCV RNA level at 12 weeks post‑therapy (SVR12) in the patient medical chart and make it available upon request.
    Related monitoringPrescriber must also maintain HCV RNA levels obtained at treatment weeks 4 and 8 as part of treatment monitoring (these records are required for renewals/extended durations).
    Renewal implicationFor regimens >16 weeks, HCV RNA at week 4 (must be <25 IU/mL) and subsequent RNA monitoring including SVR12 may be required for renewal review.
    Documentation useSVR12 documentation is used to demonstrate treatment effectiveness and must be available upon Alaska Medicaid request for authorization/renewal decisions.

    Background and Clinical Context

    Direct acting antivirals (DAAs) are oral agents approved to treat chronic hepatitis C (HCV) infection across genotypes. Treatment selection depends on HCV genotype, prior treatment experience, presence and degree of cirrhosis (Child‑Pugh class), and resistance‑associated substitutions when applicable. Prior authorization is required and approval is contingent on documentation of chronic HCV diagnosis, genotype and resistance testing when required, hepatic status (including Child‑Pugh score), prior HCV therapy history, and a signed patient readiness attestation. Prescribers are expected to monitor HCV RNA during therapy and to maintain HCV RNA at 12 weeks post‑therapy (SVR12) documentation in the medical record.

    Policy Summary
    PayerAlaska Medicaid
    PolicyDirect Acting Antivirals for Hepatitis C (HCV) — Coverage Criteria
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateN/A
    Last ReviewSep 22, 2017
    Next Review DateN/A
    Key ActionSubmit prior authorization with documentation of chronic HCV diagnosis, genotype, hepatic status (Child‑Pugh), prior therapy history, patient readiness attestation, and plan for SVR12 monitoring.
    SourceLink
    On This Page
    Coverage and Medical Necessity CriteriaWhat Providers Must Do / Authorization RequirementsDefinitions and Key TermsBackground and Clinical Context
  1. Preferred agent requirement: trial or contraindication documentation required before non-preferred agent will be approved
  2. Example preferred agent: Mavyret (when medically appropriate and available)
  3. Documentation Required

    Required Documentation with Prior Authorization

    Authorization requests must include documentation of chronic HCV diagnosis and supporting clinical information. Incomplete requests will be non-clinically denied after 7 calendar days if requested information is not provided.

    • Required with PA: diagnosis of chronic HCV, HCV genotype, viral resistance status (when applicable), hepatic status (Child-Pugh score), and HCV viral load
    • Required with PA: documentation of prior HCV therapies, dates, completion status or reason for discontinuation, and resistance data if available
    • Required with PA: HBV screening (HBsAg and anti-HBc); if HCV/HIV co-infected, include CD4 count, HIV viral load, and HIV regimen
    • Required with PA: signed patient attestation of readiness/compliance and prescriber agreement to obtain SVR12 HCV RNA
    Denial Risk

    Triggers for Denial

    Requests will be denied under specified conditions including clinical and documentation deficiencies. If incomplete information is submitted, prescribers have 7 calendar days to respond to avoid non-clinical denial.

    • Request for acute hepatitis C infection — DENY
    • Request for a non-preferred agent when a medically appropriate preferred agent is available — DENY
    • Request for a preferred agent for duration exceeding the FDA‑approved duration for the indication — DENY
    • Patient readiness not assessed or signed attestation not included — DENY
    • Active substance dependency without referral for treatment — DENY
    • Patient Child‑Pugh score > 6 (Class B or C) without management by or consultation with a liver disease specialist — DENY
    • Concomitant medications that counteract DAA efficacy or create safety risk — DENY
    • Patient age 12–18 years not managed by or in consultation with a liver disease specialist — DENY
    • Request for a non-preferred agent when a less expensive, medically appropriate preferred agent is available — DENY
    • Incomplete PA requests: prescriber has 7 calendar days to provide requested information or the PA will be non-clinically denied